*Tirzepatide, a dual agonist for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, has gained attention for its efficacy in treating type 2 diabetes and managing weight loss. Approved by the FDA for these indications, it is administered via subcutaneous injection and has shown promising results in clinical settings. Given the obesity epidemic, with approximately 75% of the U.S. population classified as obese, Tirzepatide represents a critical intervention. However, concerns about its potential to cause cancer, particularly thyroid cancer, have emerged, prompting a detailed examination of the evidence.